Wire · market
MiMedx to acquire Sanara MedTech in $350M deal
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 1 August 2026 · Fusion42 review
MiMedx has agreed to acquire Sanara MedTech for approximately $350 million in a cash-and-stock deal, expanding its surgical regenerative products portfolio with Sanara's FDA Breakthrough Device-designated OsStic BioAdhesive. The combined company projects over $400 million in revenue for 2027, with the deal expected to close by year-end pending approvals.
This Wire brief sits within Fusion42's coverage of Medtech.
◆ ◆ The Wire takeaway
Your surgical regenerative medtech market just got more competitive as MiMedx expands by acquiring a firm with a breakthrough FDA-designated device launching soon. Expect increased pressure on rivals to match this product innovation or seek partnerships before the combined company captures more market share.
◆ Coverage
1 source · 1 Aug 2026
◆ Related on Wire
◆ Topics